Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Total Non-Current Liabilities (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $35.0 as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 98.91% to $35.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $35.0, a 98.91% decrease, with the full-year FY2024 number at $10096.0, down 61.74% from a year prior.
  • Total Non-Current Liabilities was $35.0 for Q3 2025 at Ensysce Biosciences, down from $1033.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $8.4 million in Q2 2022 to a low of $35.0 in Q3 2025.
  • A 5-year average of $1.6 million and a median of $69507.0 in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 978.83% in 2021, then tumbled 99.43% in 2023.
  • Ensysce Biosciences' Total Non-Current Liabilities stood at $8.1 million in 2021, then crashed by 94.43% to $450494.0 in 2022, then crashed by 94.14% to $26388.0 in 2023, then plummeted by 61.74% to $10096.0 in 2024, then tumbled by 99.65% to $35.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Total Non-Current Liabilities are $35.0 (Q3 2025), $1033.0 (Q2 2025), and $130180.0 (Q1 2025).